MedTrace Logo

Proteomic Analysis of Serum Samples After Cardiac Arrest: a TTM-trial Substudy

NCT07017374 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 682

Last updated 2026-04-28

No results posted yet for this study

Summary

Cardiac arrest remains a large contributor to morbidity and mortality. Animal studies suggest an improvement in mortality and neurological function with hypothermia after cardiac arrest, a finding that could not be verified in large clinical trials such as Target Temperature Management after Out-of-hospital Cardiac arrest (TTM) trial. Multimodal neuroprognostication is an important tool for differentiating patients that will recover after cardiac arrest, and currently only one biomarker is in clinical use. The purpose of this study is to explore proteomics profiles in TTM trial patients in order to search for potential novel biomarkers, therapeutic targets, and to explore phenotypes of post-cardiac arrest syndrome.

Conditions

  • Cardiac Arrest (CA)
  • Proteomics

Interventions

OTHER

Proteomic analysis, targeted temperature management

Biobank serum samples from patients that were included in the TTM trial will be used for proteomic analysis. TTM trial randomised patients to targeted temperature management of 33 °C or 36 °C.

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Niklas Nielsen, Professor, MD · Lund University, Helsingborg hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017374 on ClinicalTrials.gov